HIGHLIGHTS
- who: Michael Xu et al. from the Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA have published the research work: STEAP1-4 (Six-Transmembrane Epithelial Antigen of the Prostate 1-4) and Their Clinical Implications for Prostate Cancer, in the Journal: Cancers 2022, 14, 4034. of /2022/
- what: Given the dynamic physiologic and pathologic mechanisms associated with STEAP1-4, they may have potential as therapeutic targets.
- future: Investigation is needed on many fronts. Studies are needed to better understand these pathophysiologic mechanisms. Ultimately further investigation is needed to determine whether STEAP1 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.